Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2025; 17(8): 109646
Published online Aug 15, 2025. doi: 10.4251/wjgo.v17.i8.109646
SOX plus sintilimab vs P-SOX vs SOX as neoadjuvant therapy in advanced gastric cancer: Efficacy and safety
Yi-Cong Wang, Chen-Guang Zhang, Yu-Wen Wang, Can Guo, Ting Pan, Peng-Jie Yu, Bao-Jia Cai, Rui-Hua Ding, Jia-Luo Qiang, Chen-Qian Deng, Cheng-Hao Hu, Yong-Huan Xu
Yi-Cong Wang, Can Guo, Ting Pan, Peng-Jie Yu, Bao-Jia Cai, Rui-Hua Ding, Yong-Huan Xu, Department of Gastrointestinal Oncology, The Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Yi-Cong Wang, Chen-Guang Zhang, Ting Pan, Jia-Luo Qiang, Chen-Qian Deng, Yong-Huan Xu, Graduate School, Qinghai University, Xining 810000, Qinghai Province, China
Chen-Guang Zhang, Cheng-Hao Hu, Department of Otolaryngology, The Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Yu-Wen Wang, School of Medicine, Zhejiang University, Hangzhou 310058, Zhejiang Province, China
Co-first authors: Yi-Cong Wang and Chen-Guang Zhang.
Author contributions: Wang YC and Zhang CG contributed equally as co-first authors; Wang YC and Zhang CG conceived the study, designed experiments, and wrote the primary manuscript; Yu PJ supervised the project, performed critical data analysis, and revised the manuscript; Wang YW, Guo C, and Pan T contributed to data collection, validation, and visualization; Cai BJ, Ding RH, and Xu YH assisted in experimental execution and technical support; Qiang JL, Deng CQ, and Hu CH participated in literature review, methodology development, and preliminary analysis; all authors reviewed and approved the final manuscript.
Supported by Qinghai Provincial Science and Technology Plan, No. 2023-ZJ-787.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of the Affiliated Hospital of Qinghai University, Approval number: P-SL-2024-421.
Informed consent statement: Written informed consent was obtained from all participants.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Data sharing statement: The datasets used and/or analyzed during the current study are not publicly available due to privacy or ethical restrictions.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng-Jie Yu, PhD, Professor, Vice Director, Department of Gastrointestinal Oncology, The Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China. hnypj768@126.com
Received: May 20, 2025
Revised: June 2, 2025
Accepted: July 1, 2025
Published online: August 15, 2025
Processing time: 89 Days and 12.2 Hours
Core Tip

Core Tip: This study demonstrated that the SOX combined with sintilimab (PD-1 inhibitor) significantly improved long-term survival outcomes in patients with advanced gastric cancer (GC) compared with P-SOX (albumin-bound paclitaxel plus SOX) or SOX alone, with superior 3-year overall survival (48.1% vs 30.5% and 29.0%) and early progression-free survival rates. The regimen also maintains a favorable safety profile, suggesting that it is a promising perioperative treatment option. The key prognostic factors include a tumor diameter ≤ 2 cm, well-differentiated histology, and negative lymph node status. These findings support the integration of immunotherapy into neoadjuvant strategies for locally advanced GC.